Showing 1891-1900 of 5063 results for "".
- New Interim CEO Named For Canada's Crescitahttps://practicaldermatology.com/news/new-interim-ceo-for-canadas-crescita/2458386/Dan Chicoine is now the interim Chief Executive Officer of Crescita Therapeutics Inc., a commercial dermatology company in Canada. He is replacing Greg Orleski. Mr. Chicoine will also continue to serve as the Company's Executive
- Avon Chooses Greenwich, CT Dermatologist to Champion ANEW Brandhttps://practicaldermatology.com/news/avon-chooses-greenwich-conn-dermatologist-to-champion-anew-brand/2458390/Kim Nichols, MD, is now Avon’s new consulting dermatologist. In her role, the Greenwich, Conn.-based dermatologist will help to educate Avon Representatives on the technology behind the
- Dr. Ken Washenik Named New President of International Society of Hair Restoration Surgeryhttps://practicaldermatology.com/news/dr-ken-washenik-named-new-president-of-international-society-of-hair-restoration-surgery/2458394/The International Society of Hair Restoration Surgery (ISHRS), a global non-profit medical association and a leading authority on hair loss treatment and restoration, elected Ken Washenik, MD, PhD, FISHRS, as President. The announcement took place at the ISHRS 24th</
- Doctors Welcome VOLBELLA XC for Lipshttps://practicaldermatology.com/news/doctors-welcome-volbella-xc-for-lips/2458401/Allergan’s JUVÉDERM VOLBELLA XC is here. The newly approved filler is now available for lip augmentation and correction of perioral rhytids in adults over the age of 21. Physicians can purchase VOLBELLA XC after completion of an
- FDA Clears Merz Aesthetics' Cellfina System for Long-Term Improvement of Cellulitehttps://practicaldermatology.com/news/fda-clears-merz-aesthetics-cellfina-system-for-long-term-improvement-of-cellulite/2458399/The FDA has cleared the Cellfina System from Merz Aesthetics, a division of Merz North America, for the long-term improvement in the appearance of cellulite on the buttocks and thighs of adult females with no loss of benefit for up to 3 years. Cellfina is the only FDA-cleared minimally in
- Encore Dermatology Introduces HylatopicPlus® Lotionhttps://practicaldermatology.com/news/encore-dermatology-introduces-hylatopicplus-lotion/2458402/Encore Dermatology, Inc. is expanding its line to with HylatopicPlus® Lotion in a 14 oz. bottle with pump dispenser. The Rx product relieves the burning, itching and pain experienced with various types of skin conditions, includi
- Sweden Greenlights Allergan's Double Chin-Melting BELKYRA®https://practicaldermatology.com/news/sweden-greenlights-allergans-double-chin-melting-belkyra/2458404/The Swedish Medical Products Agency has greenlighted Allergan’s BELKYRA® (deoxycholic acid) for submental fat reduction. BELKYRA® is already licensed in Canada, Australia, Iceland, Hungary, Austria, Lithuania, Estonia, Latvia, Romania, Bulgaria and Norway, as well
- Vaseline Initiative Aims to Close Skin Heath Treatment Gaphttps://practicaldermatology.com/news/vaseline-initiative-aims-to-close-skin-heath-treatment-gap/2458405/The Vaseline® Healing Project in partnership with non-profit Direct Relief is working to close the skin health treatment gap for Americans by providing skin care and training along with Vaseline® products and medical supplies for those with limited access.<
- Opdivo Stabilized Patient-reported Outcomes in Previously Treated Recurrent or Metastatic SCC of Head and Neckhttps://practicaldermatology.com/news/opdivo-stabilized-patient-reported-outcomes-in-previously-treated-recurrent-or-metastatic-scc-of-head-and-neck/2458409/Bristol-Myers Squibb Company reported new patient-reported quality-of-life data from an exploratory endpoint in the pivotal Phase 3 CheckMate -141 trial evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after platinum therapy compared to inves
- Phase 3 Study: Yervoy Improves Overall Survival in Fully Resected Stage III Melanoma Patientshttps://practicaldermatology.com/news/phase-3-study-yervoy-improves-overall-survival-in-fully-resected-stage-iii-melanoma-patients/2458408/Yervoy 10 mg/kg demonstrated superiority versus placebo on all survival endpoints in the Phase 3 trial CA184-029 (EORTC 18071) evaluating stage III melanoma patients who are at high risk of recurrence following complete surgical resection, according to Bristol-Myers Squibb Company. In the study,